Evidence map›Paper›PMID 28368402›Full record

ArticleOncogene2017

Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

V Cesarini, E Guida, F Todaro, S Di Agostino, V Tassinari, S Nicolis, R Favaro, S Caporali, P M Lacal, E Botti and 4 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. A Narrative Review of the Role of Estrogen (Receptors) in Melanoma.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

V CesariniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
E GuidaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
F TodaroDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
S Di AgostinoRegina Elena National Cancer Institute - IFO, Oncogenomic and Epigenetic Unit, Rome, Italy.
V TassinariDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
S NicolisDepartment of Biotechnology and Bioscience, University of Milan-Bicocca, Milan, Italy.
R FavaroDepartment of Biotechnology and Bioscience, University of Milan-Bicocca, Milan, Italy.
S CaporaliMolecular Oncology Laboratory, Istituto Dermopatico dell'Immacolata - IRCCS, Rome, Italy.
P M LacalMolecular Oncology Laboratory, Istituto Dermopatico dell'Immacolata - IRCCS, Rome, Italy.
E BottiDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
A CostanzoDepartment of Biomedicine, Humanitas University, Milan, Italy.
P RossiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
E A JanniniDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
S DolciDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · ITIstituto Dermopatico dell'Immacolata · ITUniversity of Milano-Bicocca · ITHumanitas University · ITIstituti Fisioterapici Ospitalieri · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a dangerous form of skin cancer derived from the malignant transformation of melanocytes. The transcription factor SOX2 is not expressed in melanocytes, however, it has been shown to be differentially expressed between benign nevi and malignant melanomas and to be essential for melanoma stem cell maintenance and expansion in vitro and in xenograft models. By using a mouse model in which BRaf

Indexed as

AnimalsCell Line, TumorDrug Resistance, NeoplasmHumansIndolesMelanomaMiceProto-Oncogene Proteins B-rafPTEN PhosphohydrolaseSOXB1 Transcription FactorsSulfonamidesVemurafenibBRAF protein, humanIndolesProto-Oncogene Proteins B-rafPTEN PhosphohydrolasePTEN protein, humanSOX2 protein, humanSox2 protein, mouseSOXB1 Transcription FactorsSulfonamidesVemurafenib

Identifiers

PMID28368402
OpenAlexW2604871868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.